LATEST NEWS

MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients

MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients

March 9, 2022 – IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant…
IN3BIO gains approval for Phase I/II clinical trial

IN3BIO gains approval for Phase I/II clinical trial

June 8, 2021 – IN3BIO Research Limited announced today that the company has received the Clinical Trial Application approval from…
Pangaea Oncology Signs 1.1 Mln contract with In3BIO

Pangaea Oncology Signs 1.1 Mln contract with In3BIO

July 8, 2020 (Reuters) – Pangaea Oncology SA: Source: https://uk.reuters.com/article/idUKL8N2EF4DZ